The cerebrospinal fluid in multiple sclerosis

F Deisenhammer, H Zetterberg, B Fitzner… - Frontiers in …, 2019‏ - frontiersin.org
Investigation of cerebrospinal fluid (CSF) in the diagnostic work-up in suspected multiple
sclerosis (MS) patients has regained attention in the latest version of the diagnostic criteria …

Proteomics in multiple sclerosis: the perspective of the clinician

D Sandi, Z Kokas, T Biernacki, K Bencsik… - International Journal of …, 2022‏ - mdpi.com
Multiple sclerosis (MS) is the inflammatory demyelinating and neurodegenerative disease of
the central nervous system (CNS) that affects approximately 2.8 million people worldwide. In …

Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis

G Hinsinger, N Galéotti, N Nabholz… - Multiple Sclerosis …, 2015‏ - journals.sagepub.com
Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic
biomarkers are still needed for optimized treatment. Objective: The objective of this paper is …

Role of Chitinase 3–like 1 as a biomarker in multiple sclerosis: a systematic review and meta-analysis

S Floro, T Carandini, AM Pietroboni… - Neurology …, 2022‏ - AAN Enterprises
Background and Objectives Multiple sclerosis (MS) is an autoimmune disease confined in
the CNS, and its course is frequently subtle and variable. Therefore, predictive biomarkers …

Recent advances in quantitative neuroproteomics

GE Craft, A Chen, AC Nairn - Methods, 2013‏ - Elsevier
The field of proteomics is undergoing rapid development in a number of different areas
including improvements in mass spectrometric platforms, peptide identification algorithms …

Biomarkers of multiple sclerosis: current findings

VK Harris, JF Tuddenham, SA Sadiq - … and neuromuscular disease, 2017‏ - Taylor & Francis
Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is
associated with chronic inflammation leading to demyelination and neurodegeneration. With …

Biomarkers of therapeutic response in multiple sclerosis: current status

VK Harris, SA Sadiq - Molecular diagnosis & therapy, 2014‏ - Springer
Multiple sclerosis (MS) is an autoimmune disease of unknown cause, in which chronic
inflammation drives multifocal demyelination of axons in both white and gray matter in the …

Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics

EL van der Ende, LH Meeter, C Stingl… - Annals of clinical …, 2019‏ - Wiley Online Library
Objective To identify novel CSF biomarkers in GRN‐associated frontotemporal dementia
(FTD) by proteomics using mass spectrometry (MS). Methods Unbiased MS was applied to …

Proteomics of multiple sclerosis: inherent issues in defining the pathoetiology and identifying (early) biomarkers

MK Sen, MSM Almuslehi, PJ Shortland… - International Journal of …, 2021‏ - mdpi.com
Multiple Sclerosis (MS) is a demyelinating disease of the human central nervous system
having an unconfirmed pathoetiology. Although animal models are used to mimic the …

Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients

B Fitzner, M Hecker, UK Zettl - Autoimmunity reviews, 2015‏ - Elsevier
Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system,
usually occurring in young adults and leading to disability. Despite the progress in …